Supplemental Figure 2 from PRAS40 Phosphorylation Correlates with Insulin-Like Growth Factor-1 Receptor-Induced Resistance to Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Figure 2: Knockdown of PRAS40 is insufficient to alter downstream signaling and therefore sensitivity to gefitinib or desIGF1. OSC19 cells were transfected with siRNA specific to PRAS40 (siRNA #1 and siRNA #2) or a scramble siRNA followed by treatment with desIGF1, gefitinib or the combination of both. (A) Immunoblot representation and quantification of PRAS40, phospho-S6 and S6 48 hours after siRNA transfection. (B) OSC19 cell viability as measured by CyQUANT 72 h following transfection and drug treatment. (C) Relative expression of TRAIL (left panel) and PINK (right panel) 48 hours after transfection and 6 hours post drug treatment as quantified by qPCR. Data represents results from at least 3 biological replicates. Asterisks represent significant changes with p<0.05 as determined by Tukey test.
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362592113